Prognostic value of circulating levels of stem cell growth factor beta (SCGF beta) in patients with Chagas' disease and idiopathic dilated cardiomyopathy

Cytokine. 2013 Mar;61(3):728-31. doi: 10.1016/j.cyto.2012.12.018. Epub 2013 Jan 26.


Chagas' disease (CD) often leads to dilated cardiomyopathy (DCM), and during its chronic stage hematopoietic stem or progenitor cells are involved in its pathological process. However, it is not clear whether stem cell growth factor (SCGF) beta can be regulated in patients with CD and idiopathic DCM. In present study, we aim to investigate the plasma SCGF beta concentration and its correlation with echocardiographic parameters and clinical outcome. In this prospective cohort study, SCGF beta levels were quantified in patients with CD (n=94), DCM (n=48), and control healthy subjects (n=25). In comparison with healthy subjects, no statistical difference can be detected in NYHA classes I-II patients. However, SCGF beta was significantly increased in advanced heart failure patients (NYHA III-IV), compared to CD patients without heart failure. There was no group difference between CD and DCM. However, despite this significant increase in advanced heart failure patients, SCGF beta had no significant correlation with echocardiographic parameters, and it cannot be used as a prognostic marker for mortality and heart transplantation. To our best knowledge, this is the first report of SCGF beta in heart failure patients. Although it is significantly increased in advanced heart failure patients caused by CD or DCM, its prognostic value for end points is minor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiomyopathy, Dilated / blood*
  • Case-Control Studies
  • Chagas Disease / blood*
  • Female
  • Hematopoietic Cell Growth Factors / blood*
  • Humans
  • Lectins, C-Type / blood*
  • Male
  • Middle Aged
  • Prognosis


  • CLEC11A protein, human
  • Hematopoietic Cell Growth Factors
  • Lectins, C-Type